While both Cvac and Stimuvax target MUC-1, they have at least one key difference. Cvac is a personalised vaccine (like Dendreon's Provenge), whereas Stimuvax is an off-the-shelf product. Personalised vaccines are believed to work better.
The link below provides a thorough analysis into the Stimuvax trials to date (the reader comments on the article are enlightening as well). I do hope that the Stimuvax phase 3 trial is successful, however there is a real possibility that it may not be. If it fails, then I hope that the market realises that that does not mean that Cvac will automatically be a failure as well. Cvac's technology is different and its phase 2 results, I believe, offer a better likelihood of success.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)